EirGenix Inc. announced that its trastuzumab biosimilar medicine which their commercial partner Sandoz plans to commercialise had received a marketing authorization from the European Commission.
EirGenix Inc. announced that its trastuzumab biosimilar medicine which their commercial partner Sandoz plans to commercialise had received a marketing authorization from the European Commission.